Key Points
- Director Eschenbach Andrew Von sold 6,059 Bausch + Lomb shares at an average price of $16.58, generating approximately $100,458. He retained 63,733 shares after the transaction, an 8.68% reduction in his position.
- Bausch + Lomb shares opened at $16.80, with the stock recently trading between a 52-week low of $13.53 and high of $18.92. The company has a $6.0 billion market capitalization and a negative price-to-earnings ratio.
- Analyst sentiment remains mixed but leans positive: five analysts rate the stock a Buy, eight a Hold, and one a Sell. The consensus target price is $18.75, while several firms recently set or raised targets to $21.
Bausch + Lomb Corporation (NYSE:BLCO - Get Free Report) Director Eschenbach Andrew Von sold 6,059 shares of the business's stock in a transaction on Friday, August 7th. The stock was sold at an average price of $16.58, for a total value of $100,458.22. Following the completion of the transaction, the director directly owned 63,733 shares in the company, valued at approximately $1,056,693.14. This represents a 8.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Bausch + Lomb Stock Up 0.1%
Shares of NYSE:BLCO opened at $16.80 on Tuesday. Bausch + Lomb Corporation has a 1 year low of $13.53 and a 1 year high of $18.92. The company has a market capitalization of $6.00 billion, a PE ratio of -35.00, a price-to-earnings-growth ratio of 0.54 and a beta of 0.55. The business has a fifty day moving average price of $16.05 and a two-hundred day moving average price of $16.39. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.55 and a quick ratio of 1.02.
Analysts Set New Price Targets
Several equities analysts recently weighed in on BLCO shares. Citigroup increased their price target on shares of Bausch + Lomb from $19.00 to $21.00 and gave the company a "buy" rating in a research report on Wednesday, July 8th. UBS Group began coverage on shares of Bausch + Lomb in a research note on Thursday, July 30th. They issued a "buy" rating and a $21.00 target price on the stock. HC Wainwright increased their target price on shares of Bausch + Lomb from $20.00 to $21.00 and gave the company a "buy" rating in a research report on Monday, August 3rd. Evercore set a $17.00 price target on shares of Bausch + Lomb in a report on Monday, July 6th. Finally, Weiss Ratings cut shares of Bausch + Lomb from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday. Five investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Bausch + Lomb has an average rating of "Hold" and a consensus target price of $18.75.
Get Our Latest Report on Bausch + Lomb
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. Glenview Capital Management LLC boosted its holdings in shares of Bausch + Lomb by 210.8% in the second quarter. Glenview Capital Management LLC now owns 1,553,855 shares of the company's stock worth $20,216,000 after acquiring an additional 1,053,855 shares during the period. Davidson Kempner Capital Management LP bought a new stake in shares of Bausch + Lomb during the 3rd quarter valued at $14,776,000. Woodline Partners LP lifted its holdings in Bausch + Lomb by 175.3% during the 3rd quarter. Woodline Partners LP now owns 861,053 shares of the company's stock worth $12,976,000 after purchasing an additional 548,230 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Bausch + Lomb by 428.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 299,671 shares of the company's stock worth $4,345,000 after purchasing an additional 242,993 shares in the last quarter. Finally, Whitebox Advisors LLC boosted its stake in Bausch + Lomb by 15.8% in the 1st quarter. Whitebox Advisors LLC now owns 1,101,854 shares of the company's stock worth $17,519,000 after purchasing an additional 150,641 shares during the period. 11.07% of the stock is currently owned by hedge funds and other institutional investors.
Bausch + Lomb Company Profile
(
Get Free Report)
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
